Dr Jessica Cale is a member of the Molecular Therapies Research group at the Centre Molecular Medicine and Innovative Therapeutics (CMMIT) at Murdoch University. In 2021 Jessica gained her PhD from Murdoch University under the supervision of Professor Steve Wilton AO and Professor Sue Fletcher AO, where she specialised in antisense oligonucleotide-mediated treatment strategies for a family of rare connective tissue disorders. Jessica currently works as a postdoctoral scientist at CMMIT, dividing her time between research for two Biotechnology companies, Senisca (Exeter, England) and Lyramid (Sydney, Australia), applying her knowledge in antisense technologies.